B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $41
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $44 to $41.
B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $44 to $41.